Ensho Therapeutics, Inc. is a privately held, clinical-stage biopharmaceutical company focused on developing breakthrough oral therapies for patients with inflammatory diseases. The company’s initial focus is on a pipeline of oral, selective small molecule inhibitors of lymphocyte homing integrin α4β7 for IBD, a mechanism already validated by a commercially available antibody. Ensho’s assets were acquired from EA Pharma Co., Ltd., a subsidiary of Eisai Co., Ltd., that is focused on gastrointestinal disease. Ensho is preparing to initiate a Phase 2 clinical program in UC with NSHO-101, the lead asset in the company’s pipeline.
Company Details
- Employees
- 9
- Founded
- 2024
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.enshorx.com
- Keywords
- Chuo-ku.
Ensho Therapeutics Questions
Ensho Therapeutics's website is https://www.enshorx.com
Ensho Therapeutics's LinkedIn profile is https://www.linkedin.com/company/enshorx
Ensho Therapeutics has
9 employees.
View email and phone details for 9
employees at Ensho Therapeutics.
Ensho Therapeutics's industry is
Biotechnology Research
Ensho Therapeutics's top competitors are
Ajinomoto Co., Inc.,
Spyre Therapeutics,
Gilead Sciences,
Caribou Biosciences,
Biogenesis,
Apogee Therapeutics,
Endpoint Health,
Eisai Us,
Candid Therapeutics,
Applied Molecular Transport.
Ensho Therapeutics's categories are Biotechnology Research
Ensho Therapeutics's founding year is 2024
